Cadila Healthcare receives US FDA's EIR report for facility in Ahmedabad SEZ

The company has received an establishment inspection report (EIR) from the US drug regulator for its oral solid dosage drug manufacturing plant

Zydus acquires derma brand Melgain from Issar Pharma
BS B2B Bureau Mumbai
Last Updated : Sep 02 2016 | 12:57 PM IST
The pharmaceutical company Cadila Healthcare Ltd has received an establishment inspection report (EIR) from the US drug regulator for its oral solid dosage drug manufacturing plant located at SEZ, Ahmedabad. “The company's oral solid dosage drug manufacturing plant located at SEZ, Ahmedabad has received an EIR from the US Food and Drug Administration (FDA) following the inspection carried out in January 2016. The receipt of EIR indicates the successful closure of the inspection points (483s) raised,” said Cadila Healthcare in a BSE filing.

The plant, for which EIR has been received by the company, is a separate manufacturing unit and is not a part of the Moraiya formulations manufacturing facility, it added.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 02 2016 | 12:53 PM IST

Next Story